MEDX.SWMEDX.SWSIX
Loading
| Metric | Q4 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +4.15% | -3.75% | +7.15% | -9.15% | -6.67% |
| Gross Profit Growth | -15.32% | -17.67% | +2.06% | +0.61% | +4.89% |
| EBITDA Growth | -39.78% | -23.35% | +147.12% | +1.55% | +13.46% |
| Operating Income Growth | -96.32% | -59.88% | -64.66% | +38.66% | +890.91% |
| Net Income Growth | -132.86% | -78.15% | +0.00% | -6.85% | +0.00% |
| EPS Growth | -132.69% | -79.31% | +0.00% | -5.56% | +0.00% |
| EPS Diluted Growth | -132.69% | -79.31% | +0.00% | -11.11% | +0.00% |
| Weighted Average Shares Growth | -0.80% | +5.60% | -0.30% | -0.14% | -0.27% |
| Weighted Average Shares Diluted Growth | -0.80% | +5.60% | -0.30% | +3.97% | -0.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +3.30% | +8.33% | +173.58% | +97.40% | -8.11% |
| Free Cash Flow Growth | -63.51% | -17.78% | +0.00% | +0.00% | +129.63% |
| Receivables Growth | +95.35% | -10.50% | -24.52% | -34.41% | +16.50% |
| Inventory Growth | +11.62% | +3.10% | -17.86% | -15.30% | -14.03% |
| Asset Growth | +3.33% | +5.99% | -13.72% | -1.96% | -3.72% |
| Book Value per Share Growth | -12.12% | -15.70% | -13.29% | -12.80% | -8.29% |
| Debt Growth | +8.97% | +11.39% | -31.70% | +1.23% | +12.07% |
| R&D Expense Growth | +18.52% | +11.38% | +3.54% | -27.13% | -20.31% |
| SG&A Expenses Growth | +26.90% | +1.90% | +24.65% | -1.05% | -5.66% |